Last reviewed · How we verify
Cisplatin & Nab Paclitaxel
Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, which inhibits microtubule dynamics.
Cisplatin is a platinum-based alkylating agent that cross-links DNA, thereby inhibiting DNA replication and transcription. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, which inhibits microtubule dynamics. Used for Ovarian cancer, Breast cancer.
At a glance
| Generic name | Cisplatin & Nab Paclitaxel |
|---|---|
| Sponsor | Joyce O'Shaughnessy |
| Drug class | Platinum-based alkylating agent and taxane |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cisplatin works by forming platinum-DNA adducts, which trigger DNA repair mechanisms and ultimately lead to cell death. Nab-paclitaxel, on the other hand, uses albumin as a carrier to deliver paclitaxel directly to the tumor site, reducing systemic toxicity and improving efficacy.
Approved indications
- Ovarian cancer
- Breast cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Anemia
- Thrombocytopenia
Key clinical trials
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC (PHASE2)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer (PHASE2)
- Study of Novel Treatment Combinations in Patients With Lung Cancer (PHASE2)
- A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin & Nab Paclitaxel CI brief — competitive landscape report
- Cisplatin & Nab Paclitaxel updates RSS · CI watch RSS
- Joyce O'Shaughnessy portfolio CI